Dogma Therapeutics Announces Global Acquisition of Oral PCSK9 Inhibitor Program by AstraZeneca
CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Dogma Therapeutics ("Dogma") has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commercial milestones.
The pursuit of a convenient, oral PCSK9-based therapy has been the singular focus of Dogma scientists for nearly a decade. PCSK9 is widely considered the exemplary target accredited by human genetics, as variants found in humans establish the needed directionality of a therapeutic. Both from a patient convenience standpoint and the potential for combination therapy, there is a need for widely-accessible oral therapies for the millions of people at risk for cardiovascular events.
Through a series of comprehensive hit-finding and validation efforts, the Dogma team discovered small molecules that directly bind to a novel binding pocket in PCSK9. Dozens of high-resolution x-ray structures of Dogma inhibitors bound to PCSK9 allowed rapid optimization to picomolar affinity with exquisite physicochemical attributes and robust LDL-C lowering when dosed orally in preclinical models of hypercholesterolemia.
"We have built a robust data package that highlights the cholesterol-lowering and safety potential of our oral PCSK9 program," noted Dogma CEO Brian Hubbard, Ph.D. "This agreement with AstraZeneca meets our strategic goal to accelerate access to patients unable to meet target LDL-C. I would like to especially thank our scientific partners - Charles River Laboratories, Viva Biotech, Anji Pharmaceuticals, and our CRO partners - for their commitment to this project and their world-class problem solving."
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said: "Raised LDL cholesterol is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide every year. Whilst PCSK9 is a well validated target for lowering LDL cholesterol it has been a hugely challenging target to inhibit with small molecules. This agreement with Dogma Therapeutics offers us the opportunity to develop the first small molecule, orally bioavailable PCSK9 inhibitor, for patients at risk of cardiovascular disease."
Since inception, Dogma has developed a highly collaborative research model that leverages scientific expertise across the globe. This collaborative model was first created with Charles River, a leading, full-service drug discovery and early-stage development company, who, with its global, integrated drug discovery and safety assessment platform, has worked on 85% of drugs approved by the FDA in 2019. In tackling this previously considered 'small molecule undruggable' target, Charles River scientists and project leads contributed medicinal and computational chemistry, structural biology, biophysics, cell biology, ADME, and PK/PD expertise. "Charles River has played an integral role in the launch and progression of Dogma with their compelling drug discovery expertise and knowledge," noted Hubbard.
"Our team is extremely proud to have worked closely with Dogma throughout the development of its oral PCSK9 inhibitor program," said Birgit Girshick, Executive Vice President, Discovery & Safety Assessment at Charles River. "This ground-breaking project could prove transformational in the management of hypercholesterolemia and cardiovascular disease."
Another key partner, Viva Biotech, is a leading structure-based, integrated drug discovery platform company. Viva has a full spectrum of early-stage drug discovery technologies from hit identification to development candidate nomination, combined with a unique equity-for-service (EFS) model. Viva has incubated more than 50 startup biotech companies similar to Dogma and plans to work with 100 more in the next 2 years.
"It was an exceptionally rewarding experience for our team to have a close partnership with Dogma during the exciting discovery phase," said Dr. Zhixiong Ye, Chief Scientific Officer at Viva Biotech. "An orally-bioavailable small molecule PCSK9 inhibitor will greatly impact the unmet medical needs of cardiovascular patients."
In addition to Viva's equity-for-service investment, Dogma received support from a syndicate of cross-border investors and corporate collaborators including JMCR Partners, CR Capital, and Anji Pharmaceuticals.
The Foley Hoag LLP team of Hemmie Chang, Adrienne Ellman, David Halstead, Nicola Lemay, Kathryn Lumb, Laura Trumbull, Yuliya Kozachenko, Chasse Osborn and Kyrsten Lundh represented Dogma.
More information on Dogma can be found here: www.dogmatherapeutics.com
Disclaimer
This press release contains forward-looking statements that can generally be identified by words such as "will," or similar expressions. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. This press release does not require an update of any forward-looking statements as a result of new information, future events or otherwise.
SOURCE Dogma Therapeutics
Share this article